There is now compelling evidence that brain tumors harbor a small population of cells characterized by their ability to undergo self-renewal and initiate tumors, termed cancer stem cells (CSCs). The development of therapeutic strategies targeted towards CSC signaling may improve the treatment of brain tumors such as malignant gliomas and medulloblastomas. Here we review the role of cancer stem cells in glioma and medulloblastoma and some of the signaling mechanisms involved in brain tumor stem cell (BTSC) biology, and discuss how these signaling pathways may represent new stem cell targets for the treatment of brain tumors. In addition, we provide illustrative immunohistochemical data on the presence of BTSCs in human gliomas and medulloblastomas, and show preliminary findings suggesting the involvement of a GPCR, the gastrin-releasing peptide receptor (GRPR), in the expansion of BTSCs in vitro.
INTRODUCTION
Gliomas and medulloblastoma are the most frequent malignant brain tumors in adults and children, respectively. The most prevalent and aggressive form of glioma is grade IV glioma (glioblastoma multiforme, GBM), which is highly malignant and resistant to standard chemotherapy. The prognosis of this tumor type remains poor despite optimal clinical treatment, with overall survival of less than 20% after one year and less than 5% after two years [1] [2] [3] . Medulloblastoma is a primitive neuroectodermal tumor that represents the most common pediatric primary malignant intracranial neoplasm. In spite of significant advances in chemo-and radiation therapy, about 30% of patients still have a low chance of being cured and survivors experience long-term neurocognitive and/or neuroendocrine sequelae [4, 5] . The development of novel therapies based on the understanding of the basic biology of brain tumors is clearly needed to improve the treatment of both gliomas and medulloblastoma.
In recent years, several studies have reported the presence of a subpopulation of tumor cells with stem-cell like properties, termed cancer stem cells (CSCs), in both gliomas and medulloblastoma. These brain tumor stem cells (BTSCs) display self-renewal properties, unlimited growth, a high migration rate, resistance to chemotherapy, and are capable *Address correspondence to these authors at the Department of Biophysics, IB, Federal University of Rio Grande do Sul (Campus do Vale/UFRGS), 91501-970 Porto Alegre, RS, Brazil and Department of Pharmacology, ICBS, Federal University of Rio Grande do Sul (Campus Centro/UFRGS), 90046-900 Porto Alegre, RS, Brazil; E-mail: lenz@ufrgs.br and rroesler@terra.com.br of recapitulating the whole tumor cell population [6] [7] [8] . BTSCs provide a target for the treatment of malignant brain tumors, and understanding the signaling pathways involved in BTSC proliferation may contribute to the development of novel therapies. In this review, we discuss the role of BTSCs in the initiation and progression of brain tumors. We summarize some of the signaling pathways critically implicated in the proliferation of BTSCs, including G-protein coupled receptors (GPCRs) as emerging targets to inhibit BTSC propagation and reduce brain tumor progression. Finally, we present original data illustrating the presence of BTSCs in glioma and medulloblastoma samples from patients and the possible role of a GPCR in stimulating the expansion of BTSCs in culture.
STEM CELLS IN THE CENTRAL NERVOUS SYS-TEM
Our understanding of BTSC biology has been enhanced by studies of normal stem cells in the central nervous system (CNS). Almost every known mammalian tissue contains a population of stem cells, which play a crucial role in tissue development and repair. Stem cells are defined as cells capable of undergoing self renewal and generating all major cell types found in the host tissue, coordinating tissue generation, maintenance, and regeneration. In the adult CNS, stem cells differentiate into distinctive mature cell types. Thus, multipotent neural stem cells (NSCs) can originate neurons, astrocytes and oligodendrocytes via the generation of lineagecommitted progenitor cell populations. Astrocytes may be derived from either oligodendrocyte type 2 astrocyte (O-2A) cells (which in turn derive from glial-restricted precursor cells) or astrocyte precursor cells, whereas oligodendrocytes derive from O-2A cells and neurons are generated from neuron-restricted precursor cells. In discrete areas of the adult brain (namely, the dentate gyrus in the hippocampus and the subventricular zone of the lateral ventricles in the forebrain), NSCs are believed to originate new neurons, a process known as neurogenesis (reviewed in [6, 9] ).
ON THE DEFINITION OF "CANCER STEM CELL"
Normal stem cells are characterized by their undifferentiated nature, high self renewal capacity and asynchronous divisions, therefore producing differentiated cells types of a particular lineage as well as maintaining a population of stem cells in a given tissue. Although CSCs can present all these features, it has been argued that the most important, and perhaps the only feature that really matters, is the tumorforming ability of an undifferentiated cancer cell [10] . Considering the genetic instability of cancer cells, it might well be that some cells in the population express stem cell markers that are expressed by normal stem cells, which are of no practical value if these cells are not able to form tumors. Therefore, the most important defining property of CSCs should be their tumor-initiation capacity, and a single bona fide CSCs should sufficient to form a tumor [11] . CSCs have been also called tumor-initiating cells (TICs), which is a more strict definition of CSCs. This is not to say that other features may not have practical and clinical relevance, as shown in so many studies that linked tumor-initiating capacity and patient survival with the presence of stem cell markers, such as CD133 in gliomas [12] . CSCs can also present features that are peculiar for the cancerous counterpart of stem cells, such as enhanced radioand chemoresistance [13] and induction of angiogenesis [14] , which are features that increase tumorigenesis.
BRAIN TUMOR STEM CELLS (BTSCS) AND BTSC MARKERS
CSCs were originally reported in acute myeloid leukemia [15] , but CSCs populations were soon identified in several solid tumors [16] . In order for a cell to be considered a BTSC, the following characteristics must be present: 1) the ability to generate tumors in xenotransplantation experiments that resemble the original tumor and that persist after serial in vivo transplantation rounds; 2) formation of neurospheres; 3) ability to undergo self renewal; and 4) expression of markers of both glial cells (astrocytes, oligodendrocytes) and neurons [6] [7] [8] .
CSCs are commonly identified by the expression of the stem cell marker CD133. This marker is expressed in only a subpopulation of glioma [17, 18] and medulloblastoma [19] cells. CD133 + glioma cells alone are capable of forming multipotent neurospheres in vitro and initiate tumors in vivo [12, 18] , and CD133
+ cells from medulloblastoma cell lines show increased ability to originate tumor xenografts [20] . However, other studies have indicated that CD133 -tumor cells can propagate experimental brain tumors as well. Thus, CD133
-glioma cells fulfilled stem cell criteria and were tumorigenic in vivo, although CD133 -glioblastomas showed a lower proliferation rate compared CD133 + xenografts [21] .
The use of CD133 as a bona fide marker of glioma BTSCs was established since the first studies indicating the presence of CSCs in gliomas were published. As mentioned above, this first round of studies showed that xenografts of CD133 -gliomas in immunocompromised mice did not form tumors, while implantation of 1000 times less CD133 + cells produced large tumors [12, 18] . CD133 expression in gliomas varies widely, with frequencies of CD133 + cells increasing with tumor grade [22, 23] . In addition, CD133 expression is a significant prognostic factor, but only when a threshold of 1% or 2% of CD133 + cells (or organization in clusters) is considered. On the other hand, CD133 mRNA expression is significantly associated with overall survival of patients [24, 25] . However, no direct correlation between the absolute percentage of CD133 + cells and patient survival has been demonstrated [24] . CD133 expression in gliomas varies from less than 1% to over 80% [26, 27] . It is quite risky, however, to define a threshold in flow cytometry experiments above which a glioma cell is considered positive for CD133. Therefore, the percentage reported often depends on the control used. Overlay of the supposedly negative and positive most often leads to the best perception of the difference between groups.
Other studies have examined CD133 expression in cultured medulloblastoma. Medulloblastoma stem cells selected by CSC medium can form 3D spheroids and display enhanced self-renewal. CD133
+ Daoy medulloblastoma cells restore native population within 18 days, whereas CD133 -cells remained negative [28] . A frequency of about 25% of CD133 + tumor spheres is formed in medulloblastoma cell cultures [18] . Ptc+/-medulloblastomas in a mouse model express about 5% of CD133 + cells, but some tumors contain as many as 56% CD133 + cells [29] .
Expression of CD133 seems to be related to considerable differences in the genetic profiles of cells, as shown by microRNA (miRNAs) profiles of CD133 + and CD133 -cell populations. miR-451, miR-486, and miR-425 were among the miRNAs upregulated in CD133 + cells when compared to CD133 -cells. Some of these miRNAs may be involved in regulation of brain differentiation and tumorigenesis [30] . The presence of CD133+ cells in samples of human glioma and medulloblastoma is illustrated in Fig. (1) .
Other markers have been reported for BTSCs. In experimental medulloblastoma, tumors from the Patched mutant mouse model of medulloblastoma were propagated not by CD133 + cells but by cells expressing the normal NSC marker CD15 [29, 31] . CD15 expression is also found in a subset of human medulloblastomas, and expression of a CD15-associated gene signature predicts survival. Although the CD15 + cells that coexpress Math1 are unable to form neurospheres, suggesting that these are not stem-like cells, the isolated CD15 + cells are progenitor-like cells with a unique capacity for tumor propagation [29] . The expression of CD15 in human medulloblastoma is shown in Fig. (2) .
Neurospheres derived from medulloblastomas express many genes characteristic of NSCs and other stem cells, including CD133, Sox2, musashi-1, bmi-1, Oct-4, Nanog maternal embryonic leucine zipper kinase, phosphoserine phosphatase and repressor element 1-silencing transcription factor (REST) [19, 32, 33] . Membrane type-1 matrix metalloproteinase (MT1-MMP) and MMP-9 contribute to the invasive phenotype during CD133 + neurosphere-like formation in medulloblastoma cells. Specific small interfering RNA gene silencing of either MT1-MMP or MMP-9 reduces the capacity of the Daoy monolayers to generate neurospheres [34] .
THE RELATIONSHIP BETWEEN BTSCS AND NSCS
It is still debated how BTSCs play a role in the formation of brain tumors, since the cellular origin of these kind of tumors and BTSCs is not completely clear. Although it is likely that BTSCs derive from normal stem cells, it is also possible that differentiated cells giving rise to tumors acquire stem cell-like properties after transformation. The first experiments that tackled this problem using transgenic mice strongly supported the hypothesis that brain tumors originated from transformation of NSCs. In these experiments, a higher incidence of tumors were observed in mice transgenic for the oncogenes Akt and Ras (K12D) regulated by the nestin promoter, which is active in NSCs, when compared to the GFAP promoter, which is active predominantly in differentiated reactive astrocytes [35] . However, after the proposal of this early model, several reports showed that GFAPexpressing cells can indeed be the origin of tumors when Akt and Ras are overexpressed together with c-Myc [36] or with deletion of Ink4a-Arf [37] . Interestingly, loss of Ink4a-Arf and overexpression of c-Myc can lead to loss of differentiation in astrocytes in culture and are common genetic alterations found in human gliomas [38] .
If NSCs were the sole cell type of origin of brain tumors, one would expect that brain regions rich in NSCs would be more often affected by tumors than regions which present fewer NSCs. Brain tumors are found in virtually all regions of the brain with no clear preference for NSC-rich areas, which may argue against the NSC origin hypothesis, unless brain tumor initiating cells are highly mobile. Lentiviral me- diated expression of H-Ras and Akt driven by the GFAP promoter in a mouse heterozygous for p53 produced tumors when lentivirus were injected into the subventricular zone and hippocampus, but not into the cortex, arguing in favor of the requirement of NSCs for the formation of brain tumors [39] . The findings from transgenic models and viral mediated expression of oncogenes or deletion of tumor suppressor genes induced by promoters can have multiple interpretations, mainly due to the lack of certainty about the cells in which a given promoter is actually active. In spite of the evidence that NSCs are the cells of origin of brain tumors, it remains unclear whether the transformation of NSCs is an absolute requirement for brain tumor formation.
SIGNALING PATHWAYS IN BTSCS
CSCs show alterations in signaling pathways involved in differentiation, such as the Notch, hedgehog and Wnt pathways. However, other pathways that are more commonly associated with tumorigenesis, such as the Ras/mitogenactivated protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTor) cascade, are altered in CSCs and seem to play a role in the maintenance of the undifferentiated phenotype (reviewed in [7, 40, 41] ). In addition, recent evidence has indicated that metabotropic glutamate receptors (mGluRs) play a role in the proliferation of brain tumor cells and suggested that GPCRs might emerge as regulators of BTSC proliferation [42] . Here we will present a few selected signaling pathways in BTSCs.
Notch
The Notch pathway is involved in several developmental processes, including CNS development. Notch is activated by activators found in neighboring cells, leading to the cleavage of its intracellular domain, which then diffuses to the nucleus, regulating gene expression. One of the main target genes of the Notch pathway is the transcription repressor Hes1, which has pleiotropic effects on several key developmental stages. Over-expression of Hes1 leads to inhibition of neurogenesis and maintenance of neural stem cells. Later in development, Hes genes promote gliogenesis [43] .
Basal Notch signaling is higher in the CD133
+ population when compared to the CD133 -population of medulloblastoma cells. Inhibition of gamma-secretase, the enzyme responsible for the cleavage of Notch, reduced viability and proliferation of medulloblastoma cells. The cell population that survived treatment was no longer able to form soft agar colonies and tumor xenografts. Notch inhibition also reduced by 5 fold the CD133 + cell population [44] .
Hedgehog
Sonic hedgehog (Shh) is a growth factor that binds to the Patched receptor (Ptc). When not activated by Shh, Ptc inhibits the activity of the GPCR Smoothened (Smo). The targets of Smo include Gli transcription. The Shh signaling has been shown to regulate neural stem cell development in many species and is present in glioblastoma, medulloblastoma, and, to a lesser extent, neuroblastoma [45] . Gli activation and Shh expression in glioma correlate with tumor grade. In addition, an intact tumor microenvironment or neurosphere conditions in vitro are necessary for Gli activity in gliomas [46] . Yang and colleagues [47] have shown that activation of Shh signaling, by deletion of Ptc, in neuronal progenitors causes medulloblastoma in mice. Deletion of Ptc in multipotent stem cells leads to expansion of the stem cell population, but only stem cells that commit with the granule lineage continue to divide and go on to form tumors. Approximately 15% of human sporadic medulloblastomas show Ptc mutations and ~ 20% of mice heterozygous for Ptc develop medulloblastoma [7] .
Wnt
The Wnt signaling pathway regulates proliferation of stem and progenitor cells in the fetal ventricular zone, as well as the post natal subventricular zone and hippocampus [48] . Wnt signaling has also been shown to play an important role in the progression of medulloblastoma, and, more recently, gliomas. Mutations in the Wnt pathway have been identified in medulloblastoma patients with Turcot's syndrome as well as in sporadic medulloblastoma [49] [50] [51] [52] . However, activation of Wnt is seen predominantly in classic tumors not showing signs of Shh signaling or chromosome 17 aberrations, suggesting they represent a unique subset of medulloblatomas [7, 53] . Some members of the Wnt family are overexpressed in astrocytomas. Experiments in vitro and in vivo using siRNA for Wnt2 and beta-catenin inhibited cell proliferation and invasive ability, and delayed tumor growth. In addition, downregulation of Wnt2 and beta-catenin was associated with decreased PI3K/p-Akt expression, indicating the interplay between Wnt/beta-catenin and PI3K/Akt signaling cascades [54] . The expression of CD133 and Wnt-1 increased in CSCs from glioblastoma compared with adherent monolayer cells [55] . The up-regulation of Axin, a negative regulator of Wnt/ -catenin signaling, significantly inhibited proliferation of glioma cells [56] . Immunohistochemical analyses have revealed that Wnt5a expression was higher in human GBM than in normal brain tissue and low-grade astrocytoma. The overexpression of Wnt5a increased the proliferation of primary culture from patient and U87MG line. In contrast, the downregulation of Wnt5a expression as the result of RNA interference reduced proliferation in these cultures and reduced tumorigenicity in vivo [57] .
PI3K, MAPKs and myc Oncogenes
Activation of the PI3K/mTor pathways is downstream of several receptors such as Shh, Wnt, tyrosine kinase receptors and GPCRs [58] . PI3K signaling pathway plays an important role in the renewal of embryonic stem cells (ESCs). PI3K inhibition by LY294002 induces differentiation of mouse ESCs [59] . Loss of PTEN, the negative regulator of the PI3K/Akt pathway, results in disorganization of the brain, probably due to a flaw in cell migration. Experiments with adult PTEN
+/-mice demonstrate that PTEN regulates migration of precursor cells in the subventricular zone to the olfactory bulb [60] . Zheng and colleagues have shown that p53 and PTEN control neural and glioma stem/progenitor cell renewal and differentiation. Concomitant deletion of p53 and PTEN in NSC increased proliferation and self-renewal reflected by neurosphere formation capacity, compared to wild-type or NSCs null for PTEN or p53 only [61] . NSCs infected with EGFRvIII (which is a constitutively activated receptor) and PTEN -/-showed increased cell proliferation, centrosome amplification, colony formation in soft agar, self-renewal, CD133 expression, and resistance to oxidative stress and ionizing radiation. In addition, these cells showed increase activity of the RAS/mitogen-activated protein kinase (ERK) and PI3K/Akt pathways. Injecting these cells in mice decreased tumor latencies and additional chromosomal aberrations [62] . Hambardzumyan et al. have demonstrated that radiation activates Akt/mTOR signaling in the perivascular nestin-expressing stem cells from medulloblastomas. These cells re-enter the cell cycle at 72 h and are responsible for the tumor recurrence [38] . In other tumors types such as prostate, the PI3K/Akt pathway is critical for CSC maintenance [63] . However, PTEN was highly expressed in CD133 + compared to CD133 -cells in the U251-MG glioma cell line [13] .
In astrocytes from p53-deficient mice, the MAPK/extracellular-regulated kinase (ERK) pathway was shown to mediate neurosphere formation [64] . Both fibroblast growth factor (FGF) and epidermal growth factor (EGF), which are used to expand NSCs and BTSCs, lead to activation of Ras/ERK pathways. FGF inhibits transcription of Shh target genes and prevents activation of a Gliresponsive promoter in fibroblasts, suggesting that it blocks Shh signaling upstream of Gli-mediated transcription. FGFmediated inhibition of Shh responses requires activation of FGF receptors as well as ERK and JNK kinases. FGF promotes differentiation of granule cell precursors in vitro and in vivo and halts proliferation of tumor cells from patched (ptc) mutant mice, a model of medulloblastoma [65] . In contrast, Schwindt and colleagues demonstrated that culturing neurospheres in suspension for 2 weeks without EGF and FGF-2 significantly increases neuronal differentiation and neurite extension when compared to cells cultured using these factors [66] .
N-myc and c-myc ongenes downstream of Wnt, Shh and MAPK respectively are altered in stem cells and brain tumors. c-myc is highly expressed in glioma CD133+ relative to non-stem glioma cells [67] . N-myc plays an important role in the growth of the cerebellum and the cerebral cortex [68] . In medulloblastoma, N-myc is amplified, it can dramatically alter the fate of preneoplastic cells, preventing differentiation and driving tumor progression [69] .
GPCRs
Although GPCRs have not featured among the main molecular regulators of BTSC proliferation, recent evidence indicates that these receptors might represent emerging BTSC targets. Glutamate, the main neurotransmitter in the CNS, is an extracellular signal regulating the proliferation and fate of NSCs in the developing and adult brain. Glutamate regulation of NSC proliferation is mediated by metabotropic glutamate receptors (mGluRs), which are GPCRs [42] . The expression of the mGlu 4 subtype of mGluR in medulloblastoma has been found to be inversely related to tumor severity, spreading, and recurrence, and a selective mGlu 4 enhancer inhibited the proliferation of medulloblastoma cell lines [70] .
Other GPCRs, such as neuropeptide receptors mediating autocrine signaling in tumors, might prove to be new cancer stem cell targets in brain tumors. The gastrin-releasing peptide receptor (GRPR), a GPCR activated by the neuropeptide GRP or the amphibian peptide bombesin, is overexpressed in many types of cancer and is importantly involved in regulating the proliferation of cancer cells [71, 72] . We have recently shown that GRPR stimulation by bombesin enhances proliferation of C6 glioma cells in vitro through a mechanism dependent on PI3K signaling [73] . Here we present our finding that bombesin induced an increase in neurosphere formation in cultured human U-87 glioma cells, suggesting that GRPR stimulation might lead to an increase BTSC expansion (Fig. 3) . Further studies might reveal that the GRPR and other GPCRs activated by neuropeptides are regulators of BTSC proliferation.
CONCLUDING REMARKS
BTSCs represent an increasingly important target for the development of more effective targeted therapies for the treatment of glioma and medulloblastoma. These stem cells are highly resistant to traditional chemotherapy, and the development of effective treatments will require the understanding of the biological mechanisms regulating BTSC proliferation and differentiation, so that signaling pathways critical for cell survival, expansion, and "stemness" can be targeted. In addition to the better understood pathways active in BTSCs, it is possible that other, less explored mechanisms such as GPCRs and neuropeptide signaling will provide new promising stem cell targets. Fig. (3) . Stimulation of a G-protein coupled receptor (GPCR) increases neurosphere formation in cultured human glioma cells. U-87MG cells (1,000) were grown in a 96 well plate for 7 days and spheres were counted from days 3 to 7 in the absence or presence of the gastrin-releasing peptide receptor (GRPR) agonist bombesin (100 nM). (A) Photomicrograph of neurosphere in cultured U-87MG cells. (B) Bombesin-induced increase in neurosphere formation in the 6th and 7th days; n = 3 replicates, 6th day, P = 0.004; 7th day, P = 0.008 compared to control cells.
